Lidocaine - Orexa
Alternative Names: ORE-001Latest Information Update: 12 Feb 2024
At a glance
- Originator Orexa
- Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Non-opioid analgesics; Small molecules
- Mechanism of Action Cell membrane permeability inhibitors; Opioid receptor agonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Postoperative ileus
Most Recent Events
- 11 Jan 2024 Phase-II clinical trials in Postoperative ileus (Prevention) in Germany (PO) (NCT05923086) (EudraCT 2022-503113-31-00-IN-002)
- 11 Jul 2023 Orexa has patent protection for mechanism of action of lidocaine
- 11 Jul 2023 Orexa plans a phase IIa trial in Cachexia & Sarcopenia (PO) in Q2 2025 (Orexa website; July 2023)